ArticleVeterinary research communications2026
Prophylactic immunomodulation with α-mannan attenuates PRRSV-induced disease in piglets.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
PRRSV poses a persistent threat to the global swine industry, yet effective control measures remain limited. This study evaluated the anti-PRRSV effects of α-mannan through in vitro and in vivo experiments. In vitro, α-mannan (25-100 µg/mL) showed no cytotoxicity and did not directly inhibit PRRSV replication. However, it exhibited immunomodulatory activity by inducing IFN-γ expression and suppressing PRRSV-induced elevation of TNF-α and IL-6. In vivo, piglets receiving prophylactic oral α-mannan (50 mg/day for 15 days before and after challenge) showed trends toward reduced PRRSV RNA loads in serum and lung tissue and alleviated pulmonary pathology (based on descriptive observations), shortened duration of detectable PRRSV RNA in oral swabs, delayed fever onset, and all survived to the end of the observation period (15 dpi). In conclusion, prophylactic α-mannan was associated with reduced PRRSV RNA load and attenuated disease severity. These findings suggest α-mannan as a promising candidate for PRRSV control.
Indexed as
Identifiers
42423861What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.